Literature DB >> 11994323

Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism.

Isabelle Bourdeau1, Céline Bard, Bernard Noël, Isabelle Leclerc, Marie-Pierre Cordeau, Manon Bélair, Jacques Lesage, Lucie Lafontaine, André Lacroix.   

Abstract

Chronic exposure to excess glucocorticoids results in cognitive and psychological impairment. A few studies have indicated that cerebral atrophy can be found in patients with Cushing's syndrome (CS), but its evolution after cure has not been studied extensively. We report the presence of apparent cerebral atrophy in CS and its reversibility after the correction of hypercortisolism. Thirty-eight patients with CS, including 21 with Cushing's disease and 17 with adrenal CS were studied. The control groups consisted of 18 patients with other non-ACTH-secreting sellar tumors and 20 normal controls. Twenty-two patients with CS were reevaluated after cure. Subjective loss of brain volume was present in 86% of patients with Cushing's disease and 100% of patients with adrenal CS. The values for third ventricle diameter, bicaudate diameter, and subjective evaluation were significantly increased in CS groups in comparison with the control group (P < or = 0.001). Imaging reevaluated at 39.7 +/- 34.1 months after achieving eucortisolism showed an improvement of the third ventricle diameter (P = 0.001), bicaudate diameter (P < 0.0005), and subjective evaluation (P = 0.05). We conclude that brain volume loss is highly prevalent in CS and is at least partially reversible following correction of hypercortisolism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994323     DOI: 10.1210/jcem.87.5.8493

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  56 in total

Review 1.  Regulation of Adult Neurogenesis and Plasticity by (Early) Stress, Glucocorticoids, and Inflammation.

Authors:  Paul J Lucassen; Charlotte A Oomen; Eva F G Naninck; Carlos P Fitzsimons; Anne-Marie van Dam; Boldizsár Czeh; Aniko Korosi
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-01       Impact factor: 10.005

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

3.  Computerized Analysis of Brain MRI Parameter Dynamics in Young Patients With Cushing Syndrome-A Case-Control Study.

Authors:  Amit Tirosh; Harish RaviPrakash; Georgios Z Papadakis; Christina Tatsi; Elena Belyavskaya; Lyssikatos Charalampos; Maya B Lodish; Ulas Bagci; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

4.  White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study.

Authors:  Patricia Pires; Alicia Santos; Yolanda Vives-Gilabert; Susan M Webb; Aitor Sainz-Ruiz; Eugenia Resmini; Iris Crespo; Manel de Juan-Delago; Beatriz Gómez-Anson
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 5.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

6.  Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease.

Authors:  Christine Mrakotsky; Peter W Forbes; Jane Holmes Bernstein; Richard J Grand; Athos Bousvaros; Eva Szigethy; Deborah P Waber
Journal:  J Int Neuropsychol Soc       Date:  2012-11-19       Impact factor: 2.892

7.  Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei--a combined MRI and H2(15)O PET study.

Authors:  Christopher M Weise; Pradeep Thiyyagura; Eric M Reiman; Kewei Chen; Jonathan Krakoff
Journal:  Neuroimage       Date:  2011-12-21       Impact factor: 6.556

8.  Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.

Authors:  Margaret F Keil; Deborah P Merke; Roma Gandhi; Edythe A Wiggs; Kathy Obunse; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-17       Impact factor: 3.478

9.  Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder.

Authors:  Eric Vermetten; Meena Vythilingam; Steven M Southwick; Dennis S Charney; J Douglas Bremner
Journal:  Biol Psychiatry       Date:  2003-10-01       Impact factor: 13.382

10.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.